APO Research
Talk to an analyst

APO RESEARCH · REPORT

Exosome CDMO

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Exosome CDMO Market Outlook and Growth Opportunities 2026

1 January 2026201 pages

Choose your research edition.

Industry ResearchExosome CDMO Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Exosome CDMO Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Exosome CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Exosome CDMO Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Exosome CDMO Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Exosome CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Exosome CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Exosome CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Exosome CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Exosome CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Exosome CDMO market include REPROCELL, Histocell, Lonza, MYCENAX, RoosterBio, Altaris LLC, Asahi Glass Co., Fortis Life Sciences and Scorpius BioManufacturing, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Exosome CDMO market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Exosome CDMO and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Exosome CDMO revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Exosome CDMO market.

Exosome CDMO Segment by Company

REPROCELL

Histocell

Lonza

MYCENAX

RoosterBio

Altaris LLC

Asahi Glass Co.

Fortis Life Sciences

Scorpius BioManufacturing

Miltenyi Bioindustry

Exothera

EXO Biologics

Porton Advanced

Elise Biopharma

Evox Therapeutics

FUJIFILM Biotechnologies

Exosome CDMO Segment by Type

Preclinical CRO

Clinical CRO

Exosome CDMO Segment by Application

Laboratory

Universities

Bio Industry

Medical Industry

Exosome CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Exosome CDMO status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Exosome CDMO key companies, revenue, market share, and recent developments.

3. To split the Exosome CDMO breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Exosome CDMO market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Exosome CDMO significant trends, drivers, influence factors in global and regions.

6. To analyze Exosome CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Exosome CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Exosome CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Exosome CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Exosome CDMO industry.

Chapter 3: Detailed analysis of Exosome CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Exosome CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Exosome CDMO in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Exosome CDMO Industry Trends Table 2. Exosome CDMO Industry Drivers Table 3. Exosome CDMO Industry Opportunities and Challenges Table 4. Exosome CDMO Industry Restraints Table 5. Global Exosome CDMO Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Exosome CDMO Revenue Share by Company (2021-2026) Table 7. Global Exosome CDMO Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Exosome CDMO Key Company Manufacturing Base & Headquarters Table 9. Global Exosome CDMO Company, Product Type & Application Table 10. Global Exosome CDMO Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Exosome CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Preclinical CRO Table 15. Significant Companies of Clinical CRO Table 16. Global Exosome CDMO Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Exosome CDMO Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Exosome CDMO Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Exosome CDMO Sales Value Share by Type (2021-2026) Table 20. Global Exosome CDMO Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Laboratory Table 22. Significant Companies of Universities Table 23. Significant Companies of Bio Industry Table 24. Significant Companies of Medical Industry Table 25. Global Exosome CDMO Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Exosome CDMO Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Exosome CDMO Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Exosome CDMO Sales Value Share by Application (2021-2026) Table 29. Global Exosome CDMO Sales Value Share by Application (2027-2032) Table 30. Global Exosome CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Exosome CDMO Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Exosome CDMO Sales Value Share by Region (2021-2026) Table 33. Global Exosome CDMO Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Exosome CDMO Sales Value Share by Region (2027-2032) Table 35. Global Exosome CDMO Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Exosome CDMO Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Exosome CDMO Sales Value Market Share by Country (2021-2026) Table 38. Global Exosome CDMO Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Exosome CDMO Sales Value Market Share by Country (2027-2032) Table 40. REPROCELL Company Information Table 41. REPROCELL Business Overview Table 42. REPROCELL Exosome CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. REPROCELL Exosome CDMO Product Portfolio Table 44. REPROCELL Recent Development Table 45. Histocell Company Information Table 46. Histocell Business Overview Table 47. Histocell Exosome CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Histocell Exosome CDMO Product Portfolio Table 49. Histocell Recent Development Table 50. Lonza Company Information Table 51. Lonza Business Overview Table 52. Lonza Exosome CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Lonza Exosome CDMO Product Portfolio Table 54. Lonza Recent Development Table 55. MYCENAX Company Information Table 56. MYCENAX Business Overview Table 57. MYCENAX Exosome CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. MYCENAX Exosome CDMO Product Portfolio Table 59. MYCENAX Recent Development Table 60. RoosterBio Company Information Table 61. RoosterBio Business Overview Table 62. RoosterBio Exosome CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. RoosterBio Exosome CDMO Product Portfolio Table 64. RoosterBio Recent Development Table 65. Altaris LLC Company Information Table 66. Altaris LLC Business Overview Table 67. Altaris LLC Exosome CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Altaris LLC Exosome CDMO Product Portfolio Table 69. Altaris LLC Recent Development Table 70. Asahi Glass Co. Company Information Table 71. Asahi Glass Co. Business Overview Table 72. Asahi Glass Co. Exosome CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Asahi Glass Co. Exosome CDMO Product Portfolio Table 74. Asahi Glass Co. Recent Development Table 75. Fortis Life Sciences Company Information Table 76. Fortis Life Sciences Business Overview Table 77. Fortis Life Sciences Exosome CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Fortis Life Sciences Exosome CDMO Product Portfolio Table 79. Fortis Life Sciences Recent Development Table 80. Scorpius BioManufacturing Company Information Table 81. Scorpius BioManufacturing Business Overview Table 82. Scorpius BioManufacturing Exosome CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Scorpius BioManufacturing Exosome CDMO Product Portfolio Table 84. Scorpius BioManufacturing Recent Development Table 85. Miltenyi Bioindustry Company Information Table 86. Miltenyi Bioindustry Business Overview Table 87. Miltenyi Bioindustry Exosome CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Miltenyi Bioindustry Exosome CDMO Product Portfolio Table 89. Miltenyi Bioindustry Recent Development Table 90. Exothera Company Information Table 91. Exothera Business Overview Table 92. Exothera Exosome CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Exothera Exosome CDMO Product Portfolio Table 94. Exothera Recent Development Table 95. EXO Biologics Company Information Table 96. EXO Biologics Business Overview Table 97. EXO Biologics Exosome CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. EXO Biologics Exosome CDMO Product Portfolio Table 99. EXO Biologics Recent Development Table 100. Porton Advanced Company Information Table 101. Porton Advanced Business Overview Table 102. Porton Advanced Exosome CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Porton Advanced Exosome CDMO Product Portfolio Table 104. Porton Advanced Recent Development Table 105. Elise Biopharma Company Information Table 106. Elise Biopharma Business Overview Table 107. Elise Biopharma Exosome CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. Elise Biopharma Exosome CDMO Product Portfolio Table 109. Elise Biopharma Recent Development Table 110. Evox Therapeutics Company Information Table 111. Evox Therapeutics Business Overview Table 112. Evox Therapeutics Exosome CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. Evox Therapeutics Exosome CDMO Product Portfolio Table 114. Evox Therapeutics Recent Development Table 115. FUJIFILM Biotechnologies Company Information Table 116. FUJIFILM Biotechnologies Business Overview Table 117. FUJIFILM Biotechnologies Exosome CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. FUJIFILM Biotechnologies Exosome CDMO Product Portfolio Table 119. FUJIFILM Biotechnologies Recent Development Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Exosome CDMO Product Image Figure 2. Global Exosome CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Exosome CDMO Market Size (2021-2032) & (US$ Million) Figure 4. Global Exosome CDMO Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Preclinical CRO Image Figure 8. Clinical CRO Image Figure 9. Global Exosome CDMO Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Exosome CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Exosome CDMO Sales Value Share by Type (2021-2032) Figure 12. Laboratory Image Figure 13. Universities Image Figure 14. Bio Industry Image Figure 15. Medical Industry Image Figure 16. Global Exosome CDMO Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Exosome CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Exosome CDMO Sales Value Share by Application (2021-2032) Figure 19. Global Exosome CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Exosome CDMO Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Exosome CDMO Sales Value (2021-2032) & (US$ Million) Figure 22. North America Exosome CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Exosome CDMO Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Exosome CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Exosome CDMO Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Exosome CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Exosome CDMO Sales Value (2021-2032) & (US$ Million) Figure 28. South America Exosome CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Exosome CDMO Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Exosome CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Exosome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Exosome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Exosome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Preclinical CRO
  • Clinical CRO
Applications
  • Laboratory
  • Universities
  • Bio Industry
  • Medical Industry
Companies covered
  • REPROCELL
  • Histocell
  • Lonza
  • MYCENAX
  • RoosterBio
  • Altaris LLC
  • Asahi Glass Co.
  • Fortis Life Sciences
  • Scorpius BioManufacturing
  • Miltenyi Bioindustry
  • Exothera
  • EXO Biologics
  • Porton Advanced
  • Elise Biopharma
  • Evox Therapeutics
  • FUJIFILM Biotechnologies

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Exosome CDMO Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Exosome CDMO Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Exosome CDMO Market Dynamics
  1. 2.1 Exosome CDMO Industry Trends
  2. 2.2 Exosome CDMO Industry Drivers
  3. 2.3 Exosome CDMO Industry Opportunities and Challenges
  4. 2.4 Exosome CDMO Industry Restraints
3 Exosome CDMO Market by Company
  1. 3.1 Global Exosome CDMO Company Revenue Ranking in 2025
  2. 3.2 Global Exosome CDMO Revenue by Company (2021-2026)
  3. 3.3 Global Exosome CDMO Company Ranking (2024-2026)
  4. 3.4 Global Exosome CDMO Company Manufacturing Base and Headquarters
  5. 3.5 Global Exosome CDMO Company Product Type and Application
  6. 3.6 Global Exosome CDMO Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Exosome CDMO Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Exosome CDMO Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Exosome CDMO Market by Type
  1. 4.1 Exosome CDMO Type Introduction
  2. 4.1.1 Preclinical CRO
  3. 4.1.2 Clinical CRO
  4. 4.2 Global Exosome CDMO Sales Value by Type
  5. 4.2.1 Global Exosome CDMO Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Exosome CDMO Sales Value by Type (2021-2032)
  7. 4.2.3 Global Exosome CDMO Sales Value Share by Type (2021-2032)
5 Exosome CDMO Market by Application
  1. 5.1 Exosome CDMO Application Introduction
  2. 5.1.1 Laboratory
  3. 5.1.2 Universities
  4. 5.1.3 Bio Industry
  5. 5.1.4 Medical Industry
  6. 5.2 Global Exosome CDMO Sales Value by Application
  7. 5.2.1 Global Exosome CDMO Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Exosome CDMO Sales Value by Application (2021-2032)
  9. 5.2.3 Global Exosome CDMO Sales Value Share by Application (2021-2032)
6 Exosome CDMO Regional Value Analysis
  1. 6.1 Global Exosome CDMO Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Exosome CDMO Sales Value by Region (2021-2032)
  3. 6.2.1 Global Exosome CDMO Sales Value by Region: 2021-2026
  4. 6.2.2 Global Exosome CDMO Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Exosome CDMO Sales Value (2021-2032)
  7. 6.3.2 North America Exosome CDMO Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Exosome CDMO Sales Value (2021-2032)
  10. 6.4.2 Europe Exosome CDMO Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Exosome CDMO Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Exosome CDMO Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Exosome CDMO Sales Value (2021-2032)
  16. 6.6.2 South America Exosome CDMO Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Exosome CDMO Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Exosome CDMO Sales Value Share by Country, 2025 VS 2032
7 Exosome CDMO Country-level Value Analysis
  1. 7.1 Global Exosome CDMO Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Exosome CDMO Sales Value by Country (2021-2032)
  3. 7.2.1 Global Exosome CDMO Sales Value by Country (2021-2026)
  4. 7.2.2 Global Exosome CDMO Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Exosome CDMO Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Exosome CDMO Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Exosome CDMO Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Exosome CDMO Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Exosome CDMO Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Exosome CDMO Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Exosome CDMO Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Exosome CDMO Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Exosome CDMO Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Exosome CDMO Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Exosome CDMO Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Exosome CDMO Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Exosome CDMO Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Exosome CDMO Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Exosome CDMO Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Exosome CDMO Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Exosome CDMO Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Exosome CDMO Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Exosome CDMO Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Exosome CDMO Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Exosome CDMO Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Exosome CDMO Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Exosome CDMO Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Exosome CDMO Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Exosome CDMO Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Exosome CDMO Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Exosome CDMO Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Exosome CDMO Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Exosome CDMO Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Exosome CDMO Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Exosome CDMO Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 REPROCELL
  2. 8.1.1 REPROCELL Company Information
  3. 8.1.2 REPROCELL Business Overview
  4. 8.1.3 REPROCELL Exosome CDMO Revenue and Gross Margin (2021-2026)
  5. 8.1.4 REPROCELL Exosome CDMO Product Portfolio
  6. 8.1.5 REPROCELL Recent Developments
  7. 8.2 Histocell
  8. 8.2.1 Histocell Company Information
  9. 8.2.2 Histocell Business Overview
  10. 8.2.3 Histocell Exosome CDMO Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Histocell Exosome CDMO Product Portfolio
  12. 8.2.5 Histocell Recent Developments
  13. 8.3 Lonza
  14. 8.3.1 Lonza Company Information
  15. 8.3.2 Lonza Business Overview
  16. 8.3.3 Lonza Exosome CDMO Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Lonza Exosome CDMO Product Portfolio
  18. 8.3.5 Lonza Recent Developments
  19. 8.4 MYCENAX
  20. 8.4.1 MYCENAX Company Information
  21. 8.4.2 MYCENAX Business Overview
  22. 8.4.3 MYCENAX Exosome CDMO Revenue and Gross Margin (2021-2026)
  23. 8.4.4 MYCENAX Exosome CDMO Product Portfolio
  24. 8.4.5 MYCENAX Recent Developments
  25. 8.5 RoosterBio
  26. 8.5.1 RoosterBio Company Information
  27. 8.5.2 RoosterBio Business Overview
  28. 8.5.3 RoosterBio Exosome CDMO Revenue and Gross Margin (2021-2026)
  29. 8.5.4 RoosterBio Exosome CDMO Product Portfolio
  30. 8.5.5 RoosterBio Recent Developments
  31. 8.6 Altaris LLC
  32. 8.6.1 Altaris LLC Company Information
  33. 8.6.2 Altaris LLC Business Overview
  34. 8.6.3 Altaris LLC Exosome CDMO Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Altaris LLC Exosome CDMO Product Portfolio
  36. 8.6.5 Altaris LLC Recent Developments
  37. 8.7 Asahi Glass Co.
  38. 8.7.1 Asahi Glass Co. Company Information
  39. 8.7.2 Asahi Glass Co. Business Overview
  40. 8.7.3 Asahi Glass Co. Exosome CDMO Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Asahi Glass Co. Exosome CDMO Product Portfolio
  42. 8.7.5 Asahi Glass Co. Recent Developments
  43. 8.8 Fortis Life Sciences
  44. 8.8.1 Fortis Life Sciences Company Information
  45. 8.8.2 Fortis Life Sciences Business Overview
  46. 8.8.3 Fortis Life Sciences Exosome CDMO Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Fortis Life Sciences Exosome CDMO Product Portfolio
  48. 8.8.5 Fortis Life Sciences Recent Developments
  49. 8.9 Scorpius BioManufacturing
  50. 8.9.1 Scorpius BioManufacturing Company Information
  51. 8.9.2 Scorpius BioManufacturing Business Overview
  52. 8.9.3 Scorpius BioManufacturing Exosome CDMO Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Scorpius BioManufacturing Exosome CDMO Product Portfolio
  54. 8.9.5 Scorpius BioManufacturing Recent Developments
  55. 8.10 Miltenyi Bioindustry
  56. 8.10.1 Miltenyi Bioindustry Company Information
  57. 8.10.2 Miltenyi Bioindustry Business Overview
  58. 8.10.3 Miltenyi Bioindustry Exosome CDMO Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Miltenyi Bioindustry Exosome CDMO Product Portfolio
  60. 8.10.5 Miltenyi Bioindustry Recent Developments
  61. 8.11 Exothera
  62. 8.11.1 Exothera Company Information
  63. 8.11.2 Exothera Business Overview
  64. 8.11.3 Exothera Exosome CDMO Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Exothera Exosome CDMO Product Portfolio
  66. 8.11.5 Exothera Recent Developments
  67. 8.12 EXO Biologics
  68. 8.12.1 EXO Biologics Company Information
  69. 8.12.2 EXO Biologics Business Overview
  70. 8.12.3 EXO Biologics Exosome CDMO Revenue and Gross Margin (2021-2026)
  71. 8.12.4 EXO Biologics Exosome CDMO Product Portfolio
  72. 8.12.5 EXO Biologics Recent Developments
  73. 8.13 Porton Advanced
  74. 8.13.1 Porton Advanced Company Information
  75. 8.13.2 Porton Advanced Business Overview
  76. 8.13.3 Porton Advanced Exosome CDMO Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Porton Advanced Exosome CDMO Product Portfolio
  78. 8.13.5 Porton Advanced Recent Developments
  79. 8.14 Elise Biopharma
  80. 8.14.1 Elise Biopharma Company Information
  81. 8.14.2 Elise Biopharma Business Overview
  82. 8.14.3 Elise Biopharma Exosome CDMO Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Elise Biopharma Exosome CDMO Product Portfolio
  84. 8.14.5 Elise Biopharma Recent Developments
  85. 8.15 Evox Therapeutics
  86. 8.15.1 Evox Therapeutics Company Information
  87. 8.15.2 Evox Therapeutics Business Overview
  88. 8.15.3 Evox Therapeutics Exosome CDMO Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Evox Therapeutics Exosome CDMO Product Portfolio
  90. 8.15.5 Evox Therapeutics Recent Developments
  91. 8.16 FUJIFILM Biotechnologies
  92. 8.16.1 FUJIFILM Biotechnologies Company Information
  93. 8.16.2 FUJIFILM Biotechnologies Business Overview
  94. 8.16.3 FUJIFILM Biotechnologies Exosome CDMO Revenue and Gross Margin (2021-2026)
  95. 8.16.4 FUJIFILM Biotechnologies Exosome CDMO Product Portfolio
  96. 8.16.5 FUJIFILM Biotechnologies Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst